Protocol Ledger

NCT07088068 · Phase III · RECRUITING

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Interventional Phase III clinical trial protocol NCT07088068 sponsored by Sanofi in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-06 Enrollment: 723 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07088068
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)723 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07088068
Protocol FieldVerified Registry Value
NCT IdentifierNCT07088068
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment723 participants (ESTIMATED)
Registered Start Date2025-08-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI